Journal: iScience

Article Title: Repurposing drugs for treating the neurobehavioral manifestations of PTEN hamartoma tumor syndrome

doi: 10.1016/j.isci.2026.115428

Figure Lengend Snippet: Compound screening in SH-SY5Y PTEN −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.

Article Snippet: Knockout of PTEN in the SH-SY5Y line (ATCC, CRL-2266) was generated using CRISPR technology.

Techniques: Activity Assay, Phospho-proteomics, Generated, Control, Labeling

Journal: IBRO Neuroscience Reports

Article Title: TNKS1 mediates the PTEN-PI3K/AKT pathway to regulate glycolysis and proliferation in gliomas

doi: 10.1016/j.ibneur.2026.01.007

Figure Lengend Snippet: TNKS1 can activate the PI3K/AKT pathway by inhibiting the expression of PTEN in glioma cells.Western blotting was used to detect the expression of PTEN in U87 and U251 cell lines (A); the CCK-8 assay was used to measure the viability of U87 and U251 glioma cells treated with different concentrations of LY294002 and 740 Y-P (B); Western blotting was also used to detect the expression of PI3K, p-AKT/AKT in U87 and U251 cell lines (C).*P < 0.05 vs si-NC，@P < 0.05 vs si-NC+Agonist，#P < 0.05 vs si-TNKS1，&P < 0.05 vs OE-TNKS1.

Article Snippet: After washing the membrane three times, it was incubated overnight at 4°C with primary antibodies targeting TNKS1 (ab83978, 1/1000, Abcam, UK), Akt (GB15689, 1/1000, Servicebio, China), p-Akt ( GB150002 , 1/1000, Servicebio, China), PI3K (GB11525, 1/1000, Servicebio, China), and PTEN (A11193, 1/1000,ABclonal,China).

Techniques: Expressing, Western Blot, CCK-8 Assay

Journal: IBRO Neuroscience Reports

Article Title: TNKS1 mediates the PTEN-PI3K/AKT pathway to regulate glycolysis and proliferation in gliomas

doi: 10.1016/j.ibneur.2026.01.007

Figure Lengend Snippet: TNKS1 can regulate the proliferation and glycolysis of glioma cells by mediating the PTEN-PI3K/AKT pathway.Cell viability of various groups in U87 and U251 cell lines (A); detection of glucose (GLU) and lactate (LA) levels in the culture supernatant of various groups in U87 and U251 cell lines using biochemical assay kits (B); qPCR was used to detect the mRNA levels of GLUT1 and HK2 in various groups of U87 and U251 cell lines (C). Statistical significance *p < 0.05, **p < 0.01, ***p < 0.001, **** p < 0.0001,"ns" P ≥ 0.05.

Article Snippet: After washing the membrane three times, it was incubated overnight at 4°C with primary antibodies targeting TNKS1 (ab83978, 1/1000, Abcam, UK), Akt (GB15689, 1/1000, Servicebio, China), p-Akt ( GB150002 , 1/1000, Servicebio, China), PI3K (GB11525, 1/1000, Servicebio, China), and PTEN (A11193, 1/1000,ABclonal,China).

Techniques:

Journal: IBRO Neuroscience Reports

Article Title: TNKS1 mediates the PTEN-PI3K/AKT pathway to regulate glycolysis and proliferation in gliomas

doi: 10.1016/j.ibneur.2026.01.007

Figure Lengend Snippet: TNKS1 can regulate the PTEN-PI3K/AKT pathway in glioma xenografts.Western blotting was used to detect the protein expression levels of PTEN, PI3K, p-AKT, and AKT in cells from each group.* P < 0.05 vs TNKS1-siRNA NC, @ P < 0.05 vs TNKS1-siRNA，# P < 0.05 vs Inhibitor.

Article Snippet: After washing the membrane three times, it was incubated overnight at 4°C with primary antibodies targeting TNKS1 (ab83978, 1/1000, Abcam, UK), Akt (GB15689, 1/1000, Servicebio, China), p-Akt ( GB150002 , 1/1000, Servicebio, China), PI3K (GB11525, 1/1000, Servicebio, China), and PTEN (A11193, 1/1000,ABclonal,China).

Techniques: Western Blot, Expressing

Journal: Frontiers in Pharmacology

Article Title: Neferine inhibits vascular smooth muscle cell proliferation and migration in atherosclerosis by targeting CYS130 and PHE252 in PTEN

doi: 10.3389/fphar.2026.1806042

Figure Lengend Snippet: Nef inhibits the proliferation and migration of MOVAS by targeting PTEN/AKT complex. (A) Detection of AKT expression by qRT-PCR (n = 4). (B) The AKT and p-AKT expression were detected by Western blotting (n = 4). (C) Co-IP analysis revealed that PTEN formed a complex with AKT. (D,E) RMSD and RMSF of PTEN-AKT complex. (F) Binding energy of PTEN-AKT complex. (G) Co-IP analysis revealed that Nef promotes PTEN/AKT complex formation. (H) Molecular dynamics simulations elucidated the effect of Nef on the PTEN/AKT complex. (I–K) RMSD, RMSF, and binding energy of the Nef-PTEN-AKT complex. (L) PTEN-specific inhibitor BpV significantly inhibited the regulation of Nef on the expression of PCNA and p-AKT (n = 4). (M) PTEN-specific inhibitor BpV significantly inhibited the regulation of the PTEN-AKT complex by Nef. * P < 0.05, ** P < 0.01, *** P < 0.001 versus model group, # P < 0.05, ## P < 0.01, ### P < 0.001 versus Nef (2 μM) group, scale column:100 μm (n = 4).

Article Snippet: Primers for PTEN, AKT, PCNA and GAPDH were designed and purchased from Sangon Biotech (Shanghai, China) ( ).

Techniques: Migration, Expressing, Quantitative RT-PCR, Western Blot, Co-Immunoprecipitation Assay, Binding Assay

Journal: Frontiers in Pharmacology

Article Title: Neferine inhibits vascular smooth muscle cell proliferation and migration in atherosclerosis by targeting CYS130 and PHE252 in PTEN

doi: 10.3389/fphar.2026.1806042

Figure Lengend Snippet: Neferine inhibits abnormal proliferation and migration of VSMCs in AS by targeting the PTEN/AKT complex.

Article Snippet: Primers for PTEN, AKT, PCNA and GAPDH were designed and purchased from Sangon Biotech (Shanghai, China) ( ).

Techniques: Migration